Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by Pacer Advisors Inc.
Pacer Advisors Inc. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,387 shares of the biopharmaceutical company’s stock after purchasing an additional 434 shares during the quarter. Pacer Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,514,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Fieldpoint Private Securities LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $130,000. Sterling Investment Advisors Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 11.2% in the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 28 shares during the period. FNY Partners Fund LP increased its stake in shares of Regeneron Pharmaceuticals by 200.0% in the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 200 shares during the period. IFP Advisors Inc increased its stake in shares of Regeneron Pharmaceuticals by 33.2% in the 2nd quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 96 shares during the period. Finally, Virtu KCG Holdings LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $206,000. Hedge funds and other institutional investors own 66.51% of the company’s stock.
Several research firms have recently commented on REGN. Canaccord Genuity set a $522.00 target price on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, July 28th. Citigroup Inc. reissued a “buy” rating and issued a $575.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, September 7th. Raymond James Financial, Inc. reissued an “outperform” rating and issued a $566.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, September 6th. Piper Jaffray Companies reissued an “overweight” rating and issued a $557.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 1st. Finally, Robert W. Baird cut Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 price objective for the company. in a research note on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $475.34.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down $0.21 during trading hours on Tuesday, reaching $385.01. The company’s stock had a trading volume of 410,508 shares, compared to its average volume of 900,662. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $41,390.00, a price-to-earnings ratio of 33.90, a price-to-earnings-growth ratio of 1.54 and a beta of 1.56. Regeneron Pharmaceuticals, Inc. has a 12-month low of $340.09 and a 12-month high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.83 by $0.16. The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.13 earnings per share. equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.
In other news, SVP Robert E. Landry sold 468 shares of the company’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $476.45, for a total value of $222,978.60. Following the transaction, the senior vice president now owns 9,099 shares of the company’s stock, valued at $4,335,218.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert E. Landry sold 189 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the transaction, the chief financial officer now directly owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Insiders sold 5,247 shares of company stock worth $2,471,445 in the last ninety days. 10.80% of the stock is owned by company insiders.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.